Carisma Therapeutics Inc. (CARM)
Carisma Therapeutics Statistics
Share Statistics
Carisma Therapeutics has 41.79M shares outstanding. The number of shares has increased by 0.5% in one year.
| Shares Outstanding | 41.79M |
| Shares Change (YoY) | 0.5% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 20.94M |
| Failed to Deliver (FTD) Shares | 1.8K |
| FTD / Avg. Volume | 0.6% |
Short Selling Information
The latest short interest is 437.88K, so 1.05% of the outstanding shares have been sold short.
| Short Interest | 437.88K |
| Short % of Shares Out | 1.05% |
| Short % of Float | 2.01% |
| Short Ratio (days to cover) | 1.28 |
Valuation Ratios
The PE ratio is -0.29 and the forward PE ratio is -0.8. Carisma Therapeutics's PEG ratio is 0.01.
| PE Ratio | -0.29 |
| Forward PE | -0.8 |
| PS Ratio | 0 |
| Forward PS | 0.8 |
| PB Ratio | -0.62 |
| P/FCF Ratio | -0.29 |
| PEG Ratio | 0.01 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Carisma Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.48, with a Debt / Equity ratio of -0.09.
| Current Ratio | 1.48 |
| Quick Ratio | 1.48 |
| Debt / Equity | -0.09 |
| Debt / EBITDA | - |
| Debt / FCF | -0.04 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-565.21K |
| Employee Count | 107 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -90.1% in the last 52 weeks. The beta is 2.86, so Carisma Therapeutics's price volatility has been higher than the market average.
| Beta | 2.86 |
| 52-Week Price Change | -90.1% |
| 50-Day Moving Average | 0.42 |
| 200-Day Moving Average | 0.8 |
| Relative Strength Index (RSI) | 20.49 |
| Average Volume (20 Days) | 301.64K |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | 0 |
| Net Income | -60.48M |
| EBITDA | 0 |
| EBIT | n/a |
| Earnings Per Share (EPS) | -1.46 |
Balance Sheet
The company has 17.91M in cash and 2.48M in debt, giving a net cash position of 15.43M.
| Cash & Cash Equivalents | 17.91M |
| Total Debt | 2.48M |
| Net Cash | 15.43M |
| Retained Earnings | -305.58M |
| Total Assets | 42.06M |
| Working Capital | 23.58M |
Cash Flow
In the last 12 months, operating cash flow was -59.92M and capital expenditures -123K, giving a free cash flow of -60.04M.
| Operating Cash Flow | -59.92M |
| Capital Expenditures | -123K |
| Free Cash Flow | -60.04M |
| FCF Per Share | -1.45 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CARM does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for CARM is $1, which is 426.3% higher than the current price. The consensus rating is "Hold".
| Price Target | $1 |
| Price Target Difference | 426.3% |
| Analyst Consensus | Hold |
| Analyst Count | 6 |
Stock Splits
The last stock split was on Mar 8, 2023. It was a backward split with a ratio of 1:20.
| Last Split Date | Mar 8, 2023 |
| Split Type | backward |
| Split Ratio | 1:20 |
Scores
| Altman Z-Score | -13.72 |
| Piotroski F-Score | 2 |